Browse studies

Find your next paid study

44 recruiting studies matching your filters

Phase 2 Trial Utilizing Zanubrutinib in Patients With Diffuse Large B-cell Lymphoma and MYD88 L265P Mutations, CD79B Mutations, NOTCH1 Truncation or Who Are CD5+ by IHC.

This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 …

Diffuse Large B-cell LymphomaDLBCL - Diffuse Large B Cell Lymphoma

Estimated

~$10 – $6,250

Virginia Commonwealth UniversityNCT06846463

Phase 1

A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced With CD19 KIR-CAR, in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administ…

B Cell LymphomaNHL, AdultMantle Cell Lymphoma+23 more

Estimated

~$10 – $8,750

Phase 2

A Phase 2 Trial of Emapalumab for the Prevention of CAR-T Cell Associated Toxicities

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-…

Large B-cell LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+4 more

Estimated

~$10 – $7,500

Marcela V. Maus, M.D.,Ph.D.NCT06550141

Phase 1

Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Toripalimab in Patients With Advanced Solid Tumors

This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced so…

Non Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaPancreas Adenocarcinoma+8 more

Estimated

~$10 – $8,750

Zumutor Biologics Inc.NCT06451497

Phase 1

A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side eff…

Non-hodgkin LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+7 more

Estimated

~$10 – $7,500

Marcela V. Maus, M.D.,Ph.D.NCT06026319

Phase 1

IOMAB-ACT: A Phase Ib/II Multi-institutional Study of 131 I-Apamistamab Followed by CD19-Targeted CAR-T Cell Therapy for Patients With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to FDA approved (commercial…

Non Hodgkin LymphomaDiffuse Large B Cell Lymphoma

Estimated

~$10 – $6,250

University of Texas Southwestern Medical CenterNCT06768905

Phase 1

A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dos…

Triple Negative Breast CancerDiffuse Large B Cell LymphomaFollicular Lymphoma+11 more

Estimated

~$10 – $8,750

OncoNano Medicine, Inc.NCT06022029

Phase 1

Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 …

Non Hodgkin Lymphoma (NHL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)+5 more

Estimated

~$10 – $6,250

Medical College of WisconsinNCT04186520